Relmada Therapeutics annual current ratio
2012
2013
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Relmada Therapeutics Current Ratio Growth & History (RLMD)
Relmada Therapeutics's current ratio was 14.62 for fiscal 2025.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 14.62 | 10.17 | +228.44% |
| 2024 | 2024-12-31 | 4.45 | −3.55 | −44.35% |
| 2023 | 2023-12-31 | 8.00 | −4.26 | −34.78% |
| 2022 | 2022-12-31 | 12.26 | −2.57 | −17.31% |
| 2021 | 2021-12-31 | 14.83 | 5.46 | +58.26% |
| 2020 | 2020-12-31 | 9.37 | −70.85 | −88.32% |
| 2019 · Dec 31 | 2019-12-31 | 80.21 | — | — |
| 2019 · Jun 30 | 2019-06-30 | 3.83 | 3.37 | +726.13% |
| 2018 | 2018-06-30 | 0.46 | −1.33 | −74.21% |
| 2017 | 2017-06-30 | 1.80 | −1.24 | −40.82% |
| 2016 | 2016-06-30 | 3.04 | 1.50 | +97.51% |
| 2015 | 2015-06-30 | 1.54 | 0.58 | +59.97% |
| 2014 | 2014-06-30 | 0.96 | — | — |
| 2013 · Dec 31 | 2013-12-31 | 0.17 | — | — |
| 2013 · Aug 31 | 2013-08-31 | 0.55 | −2.08 | −79.10% |
| 2012 · Aug 31 | 2012-08-31 | 2.62 | — | — |
Relmada Therapeutics quarterly current ratio
Q4.12
Q1.13
Q2.13
Q4.13
Q1.14
Q4.13
Q1.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 29.52 | 25.41 | +618.48% |
| Q1 2026 | 2026-03-31 | 18.26 | 12.97 | +245.30% |
| Q4 2025 | 2025-12-31 | 14.62 | 10.17 | +228.44% |
| Q3 2025 | 2025-09-30 | 2.86 | −4.03 | −58.45% |
| Q2 2025 | 2025-06-30 | 4.11 | −3.33 | −44.80% |
| Q1 2025 | 2025-03-31 | 5.29 | −1.54 | −22.53% |
| Q4 2024 | 2024-12-31 | 4.45 | −3.55 | −44.35% |
| Q3 2024 | 2024-09-30 | 6.89 | −6.07 | −46.83% |
| Q2 2024 | 2024-06-30 | 7.44 | −3.96 | −34.72% |
| Q1 2024 | 2024-03-31 | 6.82 | −6.60 | −49.16% |
| Q4 2023 | 2023-12-31 | 8.00 | −4.26 | −34.78% |
| Q3 2023 | 2023-09-30 | 12.95 | 3.95 | +43.85% |
| Q2 2023 | 2023-06-30 | 11.40 | −0.00 | −0.02% |
| Q1 2023 | 2023-03-31 | 13.42 | −1.23 | −8.39% |
| Q4 2022 | 2022-12-31 | 12.26 | −2.57 | −17.31% |
| Q3 2022 | 2022-09-30 | 9.01 | 4.02 | +80.80% |
| Q2 2022 | 2022-06-30 | 11.40 | 3.45 | +43.34% |
| Q1 2022 | 2022-03-31 | 14.65 | 6.49 | +79.58% |
| Q4 2021 | 2021-12-31 | 14.83 | 5.46 | +58.26% |
| Q3 2021 | 2021-09-30 | 4.98 | −32.04 | −86.54% |
| Q2 2021 | 2021-06-30 | 7.95 | −49.83 | −86.23% |
| Q1 2021 | 2021-03-31 | 8.16 | −42.81 | −83.99% |
| Q4 2020 | 2020-12-31 | 9.37 | −70.85 | −88.32% |
| Q3 2020 | 2020-09-30 | 37.02 | — | — |
| Q2 2020 | 2020-06-30 | 57.78 | 53.95 | +1408.37% |
| Q1 2020 · Mar 31 | 2020-03-31 | 50.97 | 49.87 | +4558.22% |
| Q4 2019 · Dec 31 | 2019-12-31 | 80.21 | 78.59 | +4832.42% |
| Q4 2019 · Jun 30 | 2019-06-30 | 3.83 | 3.37 | +726.13% |
| Q3 2019 | 2019-03-31 | 1.09 | 0.28 | +35.16% |
| Q2 2019 | 2018-12-31 | 1.63 | 0.26 | +19.20% |
| Q1 2019 | 2018-09-30 | 0.18 | −1.34 | −88.22% |
| Q4 2018 | 2018-06-30 | 0.46 | −1.33 | −74.21% |
| Q3 2018 | 2018-03-31 | 0.81 | −1.83 | −69.33% |
| Q2 2018 | 2017-12-31 | 1.36 | −2.38 | −63.59% |
| Q1 2018 | 2017-09-30 | 1.52 | −1.63 | −51.82% |
| Q4 2017 | 2017-06-30 | 1.80 | −1.24 | −40.82% |
| Q3 2017 | 2017-03-31 | 2.64 | −2.26 | −46.12% |
| Q2 2017 | 2016-12-31 | 3.75 | 0.48 | +14.53% |
| Q1 2017 | 2016-09-30 | 3.15 | 0.13 | +4.44% |
| Q4 2016 | 2016-06-30 | 3.04 | 1.50 | +97.51% |
| Q3 2016 | 2016-03-31 | 4.90 | 3.80 | +344.78% |
| Q2 2016 | 2015-12-31 | 3.27 | 2.11 | +180.67% |
| Q1 2016 | 2015-09-30 | 3.02 | 2.44 | +425.41% |
| Q4 2015 | 2015-06-30 | 1.54 | 0.58 | +59.97% |
| Q3 2015 | 2015-03-31 | 1.10 | — | — |
| Q2 2015 | 2014-12-31 | 1.17 | 1.00 | +593.39% |
| Q1 2015 | 2014-09-30 | 0.57 | — | — |
| Q4 2014 | 2014-06-30 | 0.96 | — | — |
| Q1 2014 · Feb 28 | 2014-02-28 | 0.21 | −0.64 | −74.97% |
| Q4 2013 · Dec 31 | 2013-12-31 | 0.17 | — | — |
| Q1 2014 · Nov 30 | 2013-11-30 | 0.27 | — | — |
| Q4 2013 · Aug 31 | 2013-08-31 | 0.55 | −2.08 | −79.10% |
| Q2 2013 | 2013-05-31 | 0.12 | — | — |
| Q1 2013 | 2013-02-28 | 0.85 | — | — |
| Q4 2012 | 2012-08-31 | 2.62 | — | — |
Relmada Therapeutics current ratio trends
Over the last five fiscal years, Relmada Therapeutics's current ratio increased from 9.37 to 14.62, a change of 5.25. The latest reported quarter, Q2 2026, shows 29.52.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics source filings ↗